

# **Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update**

<https://marketpublishers.com/r/CDE865B75708EN.html>

Date: June 2022

Pages: 45

Price: US\$ 3,500.00 (Single User License)

ID: CDE865B75708EN

## **Abstracts**

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

### **SUMMARY**

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Cholesteryl Ester Transfer Protein – Drugs In Development, 2022, outlays comprehensive information on the Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) – Cholesteryl ester transfer protein (CETP), also called plasma lipid transfer protein is a plasma protein that promotes the transfer of cholesteryl esters from anti-atherogenic HDLs to proatherogenic apolipoprotein B (apoB)-containing lipoproteins, including VLDLs, VLDL remnants, IDLs, and LDLs. A deficiency of CETP is associated with increased HDL levels and decreased LDL levels, a profile that is typically anti-atherogenic. The molecules developed by companies in Phase III, Phase I and Preclinical stages are 2, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Cardiovascular,

Metabolic Disorders, Central Nervous System and Infectious Disease which include indications Dyslipidemia, Acute Coronary Syndrome, Alzheimer's Disease, Atherosclerosis, Cardiovascular Disease, Coronavirus Disease 2019 (COVID-19), Diabetes, Heterozygous familial hypercholesterolemia (heFH) and Hypercholesterolemia.

Furthermore, this report also reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)

The report reviews Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics and enlists all their major and minor projects

The report assesses Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics based on mechanism of action (MoA), route of

administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) – Overview

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) – Therapeutics  
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) – Therapeutics  
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) – Companies  
Involved in Therapeutics Development

Bristol-Myers Squibb Co

Chong Kun Dang Pharmaceutical Corp

DalCor Pharmaceuticals Inc

NewAmsterdam Pharma BV

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) – Drug Profiles

CKD-508 – Drug Profile

Product Description

Mechanism Of Action

History of Events

dalcetrapib – Drug Profile

Product Description

Mechanism Of Action

History of Events

HL-16 – Drug Profile

Product Description

Mechanism Of Action

obicetrapib – Drug Profile

Product Description

Mechanism Of Action

History of Events

## Small Molecule to Inhibit CETP for Cardiovascular Disease – Drug Profile

Product Description

Mechanism Of Action

## Small Molecule to Inhibit CETP for Dyslipidemia – Drug Profile

Product Description

Mechanism Of Action

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) – Dormant Products

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) – Discontinued Products

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) – Product Development Milestones

Featured News & Press Releases

Jun 06, 2022: NewAmsterdam Pharma Shares New Data from Phase 2b ROSE Study Showing up to 82.5% of Patients with Dyslipidemia Attained LDL-c Goals

May 19, 2022: NewAmsterdam pharma to present at upcoming medical conferences new post-Hoc analyses from phase 2 ROSE trial of obicetrapib in patients with dyslipidemia

May 11, 2022: New Meta-Analysis in European Heart Journal's Cardiovascular Pharmacotherapy Examines Cholesterol Ester Transfer Protein (CETP) Inhibitors' Role in Reduction of Diabetes Risk

Apr 05, 2022: NewAmsterdam Pharma doses first patient in phase 2 trial of Obicetrapib in combination with Ezetimibe as an adjunct to high-intensity statin therapy

Mar 01, 2022: NewAmsterdam Pharma doses first patient in PREVAIL, the cardiovascular outcomes trial of obicetrapib in adults with atherosclerotic cardiovascular disease (ASCVD)

Feb 14, 2022: New review article in ESC's Cardiovascular Research Examines Cholesteryl Ester Transfer Protein (CETP) inhibition's role in reducing cardiovascular disease risk

Jan 04, 2022: NewAmsterdam Pharma doses first patient in phase 3 BROADWAY trial of obicetrapib in adults with heterozygous familial hypercholesterolemia (HeFH) and/or established atherosclerotic cardiovascular disease (ASCVD)

Nov 15, 2021: NewAmsterdam Pharma reports positive data in Phase II dyslipidemia trial

Nov 08, 2021: NewAmsterdam Pharma announces ROSE phase 2 trial results accepted for Featured Science Presentation at 2021 AHA Scientific Sessions

Jul 28, 2021: NewAmsterdam Pharma reports positive results from phase 2 study of Oral Obicetrapib demonstrating over 50% LDL-lowering as an adjunct to high-intensity statins

Jul 27, 2020: DalCor announces dal-GenE trial continues with final data expected in the first half of 2021

Jan 27, 2020: DalcOR announces Dal-gene trial to continue as planned following interim futility analysis

Dec 17, 2018: DalcOR announces completion of patient enrollment in Dal-gene, the first phase 3 precision medicine cardiovascular outcomes trial in coronary heart disease

Apr 26, 2018: Discovery Explaining the Potential Cardiovascular Benefits of a Precision Therapy Based on the Genetic Profile

Apr 05, 2018: DalCor Announces Expansion and Accelerated Enrollment of the dal-GenE Clinical Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Bristol-Myers Squibb Co, 2022

Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022

Pipeline by DalCor Pharmaceuticals Inc, 2022

Pipeline by NewAmsterdam Pharma BV, 2022

Dormant Projects, 2022

Discontinued Products, 2022

Discontinued Products, 2022 (Contd..1)

Discontinued Products, 2022 (Contd..2)

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022



## I would like to order

Product name: Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/CDE865B75708EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CDE865B75708EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970